1.Clinical analysis of 251 cases of soft tissue sarcomas.
Ying-qiang SHI ; Xiang-yun ZONG ; Jian WANG ; Shu LI
Chinese Journal of Surgery 2003;41(2):116-118
OBJECTIVETo explore the therapeutic principles and prognostic factors of soft tissue sarcoma.
METHODSTwo hundred and fifty-one patients with soft tissue sarcoma (STS) treated at Shanghai Cancer Hospital during 1986 - 1990 were reviewed retrospectively.
RESULTSThe 1-, 3-, 5-, 10-year tumor-free survival rates were 67.74%, 57.16%, 52.41%, 38.60%, respectively. The overall survival rates for 1, 3, 5 and 10 years were 81.01%, 67.75%, 60.79%, and 49.23% respectively. Log-rank test showed that the patients with different pathological findings, histological grades, mass location and size, anatomical depth, and surgical margin showed different outcomes. Whether the sarcomas invaded the vessels or metastasized would influence the survival rates. The patients who underwent different interventions or operations also had different outcomes. The prognosis of STS was associated with age, histological type, histological grade, tumor size, surgical margin and metastasis according to the Cox regression analysis.
CONCLUSIONDuring the treatment of STS, wide-resection, especially 3-dimensional resection, comprehensive treatment and individualized treatment should be advocated.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Radiotherapy, Adjuvant ; Retrospective Studies ; Sarcoma ; mortality ; pathology ; therapy ; Soft Tissue Neoplasms ; mortality ; pathology ; therapy ; Survival Analysis ; Survival Rate
2.High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas.
Young Bae CHOI ; Eun Sang YI ; Ji Won LEE ; Keon Hee YOO ; Ki Woong SUNG ; Hong Hoe KOO
Journal of Korean Medical Science 2016;31(7):1055-1062
Despite increasing evidence that high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) might improve the survival of patients with high-risk or recurrent solid tumors, therapy effectiveness for bone and soft tissue sarcoma treatment remains unclear. This study retrospectively investigated the feasibility and effectiveness of HDCT/auto-SCT for high-risk or recurrent bone and soft tissue sarcoma. A total of 28 patients (18 high-risk and 10 recurrent) underwent single or tandem HDCT/auto-SCT between October 2004 and September 2014. During follow-up of a median 15.3 months, 18 patients exhibited disease progression and 2 died of treatment-related toxicities (1 veno-occlusive disease and 1 sepsis). Overall, 8 patients remained alive and progression-free. The 3-year overall survival (OS) and event-free survival (EFS) rates for all 28 patients were 28.7% and 26.3%, respectively. In the subgroup analysis, OS and EFS rates were higher in patients with complete or partial remission prior to HDCT/auto-SCT than in those with worse responses (OS, 39.1% vs. 0.0%, P = 0.002; EFS, 36.8% vs. 0.0%, P < 0.001). Therefore, careful selection of patients who can benefit from HDCT/auto-SCT and maximal effort to reduce tumor burden prior to treatment will be important to achieve favorable outcomes in patients with high-risk or recurrent bone and soft tissue sarcomas.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Bone Neoplasms/mortality/pathology/*therapy
;
Child
;
Child, Preschool
;
Disease-Free Survival
;
Female
;
Follow-Up Studies
;
Humans
;
Infant
;
Male
;
Retrospective Studies
;
Sarcoma/mortality/pathology/*therapy
;
Soft Tissue Neoplasms/mortality/pathology/*therapy
;
*Stem Cell Transplantation
;
Survival Rate
;
Transplantation, Autologous
;
Treatment Outcome
;
Young Adult